Analysts think NAGE stock price could decrease by -6%
Jun 09, 2025, 11:26 AM
9.92%
What does NAGE do
Chromadex is a Los Angeles-based bioscience company focused on developing proprietary ingredient technologies, including NAD+ research. It operates through Consumer Products, Ingredients, and Analytical Reference Standards segments, employing 106 staff since its IPO in 2007.
8 analysts think NAGE stock price will decrease by -5.52%. The current median analyst target is $12.24 compared to a current stock price of $12.96. The lowest analysts target is $9.70 and the highest analyst target is $16.80.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
